2024-03-28T12:00:34Z
https://tsukuba.repo.nii.ac.jp/oai
oai:tsukuba.repo.nii.ac.jp:00049478
2022-04-27T09:22:04Z
2780:3353
2780:5104
2780:919
2780:970
3:62:5298:7336
Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
関根, 郁夫
セキネ, イクオ
SEKINE, Ikuo
中澤, 健介
ナカザワ, ケンスケ
NAKAZAWA, Kensuke
佐藤, 浩昭
サトウ, ヒロアキ
SATOH, Hiroaki
檜澤, 伸之
ヒザワ, ノブユキ
HIZAWA, Nobuyuki
Shiozawa, Toshihiro
Aida, Yuka
Watanabe, Hiroko
Kurishima, Koichi
© 2018 The Author(s) Published by S. Karger AG, Basel www.karger.com/cro
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
Background: Sensitive-relapsed small-cell lung cancer (SCLC) is thought to be sensitive to chemotherapy; therefore, second-line chemotherapy is recommended. Although platinum rechallenge is performed in the second-line chemotherapy for sensitive-relapsed SCLC, it remains unclear whether such a strategy is effective. Methods: We retrospectively analyzed the outcome of rechallenge chemotherapy for sensitive-relapsed SCLC. The endpoints of this study were progression-free survival from the time of relapse (PFS-Re) and overall survival from the time of relapse (OS-Re). We also compared the toxicity profile of rechallenge chemotherapy to that of first-line chemotherapy. Results: Of the 133 SCLC patients who received first-line treatment, 20 patients satisfied the definition of sensitive relapse and received rechallenge chemotherapy. Combined carboplatin and etoposide was the most commonly used rechallenge regimen, and 17 (85%) received it at a reduced dose due to hematological toxicity during the first-line treatment. Median PFS-Re and OS-Re were 4.5 months (95% CI: 3.5–5.4) and 10.5 months (95% CI: 7.9–13.0), respectively. There was no association between dose adjustment and survival. The frequency of hematologic toxicity tended to be lower with rechallenge than first-line treatment. The incidence of grade 3 febrile neutropenia decreased from 40% in first-line treatment to 15% in rechallenge. Conclusion: Platinum rechallenge could be a useful second-line option for sensitive-relapsed SCLC, having favorable efficacy and safety. Dose adjustment at rechallenge based on the toxicity profile during the first-line chemotherapy could reduce toxicity without weakening efficacy.
Karger
2018-09
eng
journal article
http://hdl.handle.net/2241/00154946
https://tsukuba.repo.nii.ac.jp/records/49478
30323752
10.1159/000492780
1662-6575
AA12780955
Case Reports in Oncology
11
3
622
632
https://tsukuba.repo.nii.ac.jp/record/49478/files/CRO_11-3.pdf
application/pdf
962.5 kB
2019-04-04